Literature DB >> 17307485

Unusual complication of heparin-induced thrombocytopenia after mitral valve surgery: spontaneous rupture of spleen.

Christina Mitchell1, Catherine A Riley, Bobbak Vahid.   

Abstract

A 64-year-old man presented with cardiac tamponade 2 weeks after mitral valve surgery. The patient was anticoagulated for persistent atrial fibrillation after cardiac surgery. A pericardial catheter was placed. Five days after presentation the patient was started on intravenous heparin infusion. The patient had abdominal pain and hypotension develop. A splenic hematoma was diagnosed and a splenectomy was performed. Pathology showed multiple fibrin thrombi in the spleen. The heparin-associated antibodies were detected. Heparin-induced thrombocytopenia is a potentially fatal condition in patients requiring heparin after cardiac surgery. Evaluation for heparin-associated antibodies in these patients may be warranted before heparin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307485     DOI: 10.1016/j.athoracsur.2006.08.047

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Heparin-induced thrombocytopenia presenting as splenic hemorrhage following cardiac surgery: a case report.

Authors:  Joseph Ferry; Samuel Youssef; Pierce Wu; Livia Hegerova
Journal:  Thromb J       Date:  2021-01-19

Review 2.  613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review.

Authors:  F Kris Aubrey-Bassler; Nicholas Sowers
Journal:  BMC Emerg Med       Date:  2012-08-14

3.  Atraumatic splenic rupture precipitated by splenic vein thrombosis.

Authors:  Qiao Zhou; Chirag Shah; Jean-Michel Arthus; Harlan Vingan; John Agola
Journal:  Radiol Case Rep       Date:  2016-03-15

4.  A fatal complication after repair of post-infarction ventricular septal rupture: heparin-induced thrombocytopenia with thrombosis.

Authors:  Yunus Nazli; Necmettin Colak; Bora Demircelik; Mehmet Faith Alpay; Omer Cakir; Kerim Cagli
Journal:  Cardiovasc J Afr       Date:  2015-05-23       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.